Perception of XTAMPZA® ER and other Abuse-Deterrent Opioid Formulations on the Internet

INTRODUCTION

The Web Monitoring Program from the Researched Abuse, Diversion and Addiction-Related Surveillance (RADARS®) System collects information on drug use and abuse via surveillance of internet postings.

Internet anonymity allows posters to reveal patient experiences that might not otherwise be captured in traditional epidemiological studies.

XTAMPZA® ER is an extended-release (ER), abuse-deterrent formulation (ADF) oxycodone product that uses DETERx® technology designed to discourage manipulation for purposes of abuse.

METHODS

The universe of public websites on the internet (over 150,000,000 websites) were scraped to find online posts made from 2018-2019.

- Included posts must mention 1) an explicit product name, or 2) tablet/capsule formulations along with ER vs immediate-release (IR) information
- Sentiment is defined as the dominating view or opinion of a drug within the post. Qualitative research methods were used to categorize posts as negative, positive, or neutral sentiment, including 3 subtypes.
  - Positive sentiments: 1) Promote therapeutic benefit, 2) Discourage abuse, 3) Refer to the product in another positive way
  - Negative sentiments: 1) Discourage therapeutic benefit, 2) Promote abuse, 3) Refer to the product in another negative way (e.g., side effect)

RESULTS

Figure 1: Overall Sentiment of XTAMPZA® ER and Comparators

Example post discouraging abuse:
*The replacement I was referring to is Xtampza ER, which they say is an oxycodone but harder to abuse by crushing it.*

Figure 2: Positive Sentiment of XTAMPZA® ER and Comparators

Example post for other negative:
*He switched to Xampza, which caused extreme nausea and vomiting.*

CONCLUSIONS

- Overall, sentiment of XTAMPZA ER was more positive and less negative than other ADF ER opioids
- Nearly zero promotion of abuse of XTAMPZA ER on the web, unlike other ADF ER opioids or IR oxycodone
- There was more discouragement of abuse of XTAMPZA ER than IR oxycodone products

LIMITATIONS

- Some websites (e.g., Facebook, BlueLight) prohibit public web scraping, and these sites could include important information not captured here
- Categorization of posts was limited to what individuals divulge, and therefore some posts might not be included because key information (e.g., formulation) is missing
- Results were from 2018-2019, and patterns might change over time

DISCLOSURE

The RADARS® System is supported by subscriptions from pharmaceutical manufacturers, government and non-government agencies for surveillance, research and reporting services. RADARS System is the property of Denver Health and Hospital Authority, a political subdivision of the State of Colorado. Denver Health retains exclusive ownership of all data, databases and systems. Subscribers do not participate in data collection nor do they have access to the raw data. This research was sponsored by Collegium Pharmaceutical.

XTAMPZA® ER is a registered trademark of Collegium Pharmaceutical.